Status:
UNKNOWN
Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer
Lead Sponsor:
Istituto Clinico Humanitas
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Aim of the present retrospective study is to evaluate molecular factors of primary resistance to tyrosine kinase inhibitors in metastatic non small cell lung cancer (NSCLC) patients. The investigators...
Detailed Description
Non small cell lung cancer patients.
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of NSCLC (non small cell lung cancer) with available tumor tissue for mutational analysis
- Metastatic disease treated with gefitinib or erlotinib
- Presence of at least one measurable lesion according to RECIST criteria
Exclusion
- No tumor tissue available
- No clinical data available
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2011
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01163058
Start Date
June 1 2010
End Date
July 1 2011
Last Update
July 29 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Rozzano, Milano, Italy, 20059